Abivax Gears Up for Blockbuster IBD Drug Launch with Full War Chest

PARIS, France – March 23, 2026 – Clinical-stage biotechnology company Abivax today signaled its transition from a development-focused firm to a commercial-ready powerhouse, announcing a strong financial position for 2025 and pivotal updates on its lead drug candidate, obefazimod. With a cash runway extending into late 2027 and a bolstered leadership team, the company is marching confidently towards a late Q2 2026 data readout for its Phase 3 ulcerative colitis (UC) trial, a milestone that could redefine treatment for millions suffering from the chronic inflammatory disease.

In a comprehensive update, Abivax reported a cash, cash equivalents, and short-term investment position of €530.4 million as of year-end 2025. This formidable financial standing is largely thanks to a successful $700.3 million public offering completed in July 2025, positioning the company to execute its ambitious clinical and commercial strategies without near-term financial constraints.

Marc de Garidel, CEO of Abivax, commented on the company's momentum: “With a strong financial foundation, we are well positioned to execute on our strategic priorities and prepare for the future. We are pleased with the recent DSMB safety update from our ABTECT maintenance trial and remain on track to report topline results from our ABTECT-UC maintenance trial in late Q2 2026.”

A New Hope for Ulcerative Colitis Patients

The most significant clinical news came from an independent Data Safety Monitoring Board (DSMB) meeting on March 18, 2026. The board reviewed safety data from the ongoing ABTECT Phase 3 maintenance trial for obefazimod in moderately to severely active UC and found no new safety signals. The update is particularly meaningful as it included data from 100% of randomized patients, with nearly 90% having already completed the 44-week trial. This positive safety profile reinforces findings from earlier studies and is a critical hurdle cleared on the path to regulatory submission.

Obefazimod stands apart in a crowded inflammatory bowel disease (IBD) market due to its novel mechanism of action. It is a first-in-class oral, once-daily small molecule that works by upregulating a specific microRNA, miR-124, which acts as a natural “physiological brake” on inflammation. This unique approach differs from existing biologics and JAK inhibitors that target specific inflammatory pathways, offering a potential new option for patients, especially those who have failed other advanced therapies.

Previous data from the pivotal Phase 3 ABTECT induction trials, which enrolled over 1,200 patients, demonstrated obefazimod's potent efficacy. The 50mg dose met its primary endpoint of clinical remission at week eight with a robust 16.4% placebo-adjusted rate. Critically, the drug showed clinically meaningful improvements across all key secondary endpoints and was effective even in a difficult-to-treat population that had previously failed biologics or JAK inhibitors. Long-term data from a two-year Phase 2b study further confirmed its durable efficacy and consistent safety, with 52.5% of patients achieving clinical remission after 96 weeks of treatment.

Fueling the Path to Market

Abivax's financial disclosures reveal a company in full execution mode. The firm’s cash runway, projected to last into the fourth quarter of 2027, provides ample resources to see obefazimod through its final clinical stages, potential regulatory approval, and initial commercial launch. This financial strength allows the company to operate from a position of power, whether it chooses to commercialize independently or seek a strategic partner.

Reflecting its late-stage focus, research and development (R&D) expenses rose to €177.8 million in 2025. This increase was not arbitrary but strategically allocated. A significant portion was dedicated to Chemistry, Manufacturing, and Controls (CMC) activities—a crucial investment to ensure the company can produce obefazimod at a commercial scale. Further funds were channeled into the clinical program for Crohn's disease, another major form of IBD, with a Phase 2b induction trial expected to complete in Q4 2026. This dual-indication strategy could significantly expand obefazimod’s potential market, which analysts estimate could reach $30 billion for IBD by 2030.

Contingent on positive data from the upcoming maintenance trial readout, Abivax plans to submit a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe in the fourth quarter of 2026, setting the stage for a potential market entry in 2027.

Forging a Commercial Juggernaut

Perhaps the clearest signal of Abivax’s evolution is its strategic reinforcement of the senior leadership team. The company announced the appointment of Michael Nesrallah as Chief Commercial Officer, a move that brings deep IBD market expertise in-house. Nesrallah previously served as Vice President and U.S. Franchise Head for Takeda's IBD business, where he was instrumental in driving the significant growth of the blockbuster drug Entyvio. His experience in launching and scaling a leading IBD therapy is invaluable as Abivax lays the groundwork for its own launch.

“Abivax is entering an exciting new chapter, and I’m thrilled to be joining the Company at such a pivotal moment,” said Nesrallah. “We have a meaningful opportunity ahead to further strengthen our commercial capabilities to prepare for the successful launch of obefazimod, if approved, which has the potential to truly make a difference for patients.”

To complement its commercial preparations, Abivax also hired Keith Fournier, PhD, as Senior Vice President of Global Regulatory Affairs, and Maurus de la Rosa, PhD, as Senior Vice President of Research. Fournier’s experience at EMD Serono and AbbVie will be critical in navigating the complex global regulatory landscape, while de la Rosa’s deep background in immunology from Sangamo Therapeutics and Takeda will drive the company's future research pipeline. These hires demonstrate a holistic strategy to build a fully integrated biopharmaceutical company capable of not only launching a drug but also sustaining long-term innovation.

With a promising and differentiated drug candidate, a fortified balance sheet, and a newly assembled team of seasoned executives, Abivax is methodically checking all the boxes required for a successful transition from clinical development to commercial reality. The entire IBD community—patients, physicians, and investors alike—will be watching closely as the company approaches its next set of critical milestones.